Daiichi Sankyo Company, Ltd. announced on Monday that SAVAYSA, a once-daily, oral, selective factor Xa-inhibitor, is now available in pharmacies within the United States. Read More »

Alkermes, PLC, said on Monday that it has produced positive results from a phase one, randomized, double-blind clinical study of ALKS 8700, an oral monomethyl fumarate (MMF) molecule in development as a multiple sclerosis (MS) treatment. Read More »

Genentech, a member of the Roche group, said on Friday that the U.S. Food and Drug Administration (FDA) approved Lucentis, the first eye medicine sanctioned to treat diabetic retinopathy (DR) with diabetic macular edema (DME). Read More »

TeaserUpsher-Smith Laboratories, Inc. announced Monday that a new saving and support program is available for patients who have been prescribed Qudexy XR extended-release capsules. Read More »

The U.S. Food and Drug Administration said on Tuesday that is has approved the use of Pfizer's palbociclib oral capsules, in combination with letrozole, to treat advanced breast cancer. Read More »

Acura Pharmaceuticals said on Thursday that it has launched NEXAFEDÂ Sinus Pressure + Pain, a pseudoephedrine, methamphetamine-resistant, immediate-release tablet that relieves congestion, pain and fever from colds and allergies. Read More »

Pharmacy Today released the findings of its annual survey on over-the-counter (OTC) products on Thursday, conducted by the American Pharmacists Association, revealing which OTC products were recommended most frequently by U.S. pharmacists during July 2014. Read More »

An American Pharmacists Association (APhA) official released a statement on Thursday, stressing the important role of childhood and booster vaccinations in the protection of individual lives and overall public health. Read More »

TeaserHelsinn Healthcare S.A. Read More »

TeaserAlbireo announced Thursday that it is beginning a phase II trial with the company’s lead compound for cholestatic liver disease and NASH, A4250. Read More »

TeaserConcert Pharmaceuticals announced Wednesday that James V. Read More »

Daiichi Sankyo Co., Ltd., said Wednesday that it has enrolled the first patients in its initial large-scale and multinational clinical studies program to assess the efficiency and safety of mirogabalin, an investigational treatment for diabetic peripheral neuropathic (DPNP) and postherpetic neuralgia (PHN). Read More »

Pfizer said on Wednesday that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ, a medication for treating moderate to severe chronic plaque psoriasis. Read More »

TissuGlu, the first tissue adhesive permitted for internal use, was approved Wednesday by the U.S. Read More »

Under a final agreement between AstraZeneca and Actavis, AstraZeneca will procure the rights to Actavis’ proprietary respiratory business in the United States and Canada, the two companies announced on Feb. 5. Read More »

Amgen’s Phase 3 study assessing the safety and effectiveness of biosimilar candidate ABP 501 versus Humira in patients with moderate to sever rheumatoid arthritis revealed positive results. Read More »

Vyvanse (lisdexamfetamine dimesylate) was approved by the U.S. Food and Drug Administration (FDA) on Friday as the first medication permitted to treat binge-eating disorder in adults. Read More »

The CVS/pharmacy mobile app has been fully revamped, with a new interface and enhanced features that aim to offer customers easier access to tools for health management and shopping directly from their handheld devices. Read More »

Mannkind Corporation and Sanofi announced on Feb. 3 that Afrezza (insulin human) Inhalation Powder is now available in U.S. Read More »

Merck announced on Feb. 3 that BELSOMRA (suvorexant), a medication for the treatment of insomnia in adults, is available in United States Pharmacies. Read More »